GSEP
BCRX icon

Golden State Equity Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Golden State Equity Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$68.5K Buy
11,430
+505
+5% +$2.93K 0.02% 355
2023
Q3 		$77.3K Hold
10,925
– – 0.02% 333
2023
Q2 		$76.9K Hold
10,925
– – 0.02% 365
2023
Q1 		$91.1K Buy
+10,925
New +$105K 0.05% 211
2022
Q1 		$186K Hold
11,435
– – 0.09% 181
2021
Q4 		$158K Buy
+11,435
New +$151K 0.08% 165

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Golden State Equity Partners's BCRX Position: Q4 2023 in Review

Golden State Equity Partners increased its BioCryst Pharmaceuticals (BCRX) stake by 4.6% in Q4 2023, buying an estimated $2.93K and bringing the position to 11,430 shares worth $68.5K. The position accounts for 0.02% of the portfolio, ranked #355.

Golden State Equity Partners first reported a position in BCRX in Q4 2021 and has held it in 6 quarters since. The position peaked at $186K in Q1 2022. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

  • Golden State Equity Partners held 11,430 shares of BioCryst Pharmaceuticals worth $68.5K as of Q4 2023.
  • Golden State Equity Partners bought 505 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $2.93K.
  • BioCryst Pharmaceuticals made up 0.02% of Golden State Equity Partners's portfolio in Q4 2023, its #355 holding.
  • Golden State Equity Partners first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 6 quarters since.
  • Golden State Equity Partners's BioCryst Pharmaceuticals position peaked at $186K in Q1 2022.
  • 235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on Golden State Equity Partners's 13F filing for Q4 2023, filed 2 Feb 2024.